STOCK TITAN
  1. Home
  2. Sec-filings
  3. DNLI
  4. [8-K] Denali Therapeutics Inc. Reports Material Event

Denali Therapeutics (NASDAQ: DNLI) details 2026 outlook, JPM event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Denali Therapeutics Inc. filed a current report to share that it has issued a press release outlining an update on its programs and expected milestones for 2026, and its planned participation in the 44th Annual J.P. Morgan Healthcare Conference. The press release is provided as Exhibit 99.1 and is incorporated by reference. The company notes that the information under Regulation FD in this report, including Exhibit 99.1, is being furnished rather than filed, which limits how it is treated under securities law.

Positive

  • None.

Negative

  • None.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Understanding 8-K Material Events →
0001714899FALSE00017148992026-01-062026-01-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 6, 2026
Denali Therapeutics Inc.
(Exact name of registrant as specified in its charter)
Delaware001-3831146-3872213
(State or other jurisdiction of(Commission(I.R.S. Employer
incorporation)File Number)Identification No.)
161 Oyster Point Blvd.
South San Francisco, California 94080
(Address of principal executive offices, including zip code)

(650) 866-8547
(Registrant’s telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last reports)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol (s) Name of each exchange on which registered
Common Stock, par value $0.01 per shareDNLINasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐




Item 7.01     Regulation FD Disclosure.

On January 6, 2026, Denali Therapeutics Inc. (the “Company”) issued a press release announcing an update on its programs and expected milestones for 2026 and the Company’s participation in the 44th Annual J.P. Morgan Healthcare Conference.

A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information furnished in this Item 7.01 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01     Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.
Description
99.1
Denali Therapeutics 2026 Outlook Press Release
104
Cover Page Interactive Data File (formatted as Inline XBRL)


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DENALI THERAPEUTICS INC.
Date:January 6, 2026By:/s/ Alexander O. Schuth
Alexander O. Schuth, M.D.
Chief Operating and Financial Officer


Source: View Original Filing on SEC EDGAR

FAQ

What did Denali Therapeutics (DNLI) disclose in this 8-K filing?

Denali Therapeutics disclosed that it issued a press release providing an update on its programs and expected milestones for 2026 and its participation in the 44th Annual J.P. Morgan Healthcare Conference.

Which exhibit is attached to Denali Therapeutics' (DNLI) 8-K about its 2026 outlook?

The filing attaches Exhibit 99.1, titled "Denali Therapeutics 2026 Outlook Press Release," along with Exhibit 104 for the cover page interactive data file formatted as Inline XBRL.

How is the information in Denali Therapeutics' (DNLI) 8-K treated under securities laws?

The company states that the information furnished under Item 7.01 and Item 9.01, including Exhibit 99.1, is furnished and not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, unless specifically incorporated by reference elsewhere.

What event is Denali Therapeutics (DNLI) highlighting in relation to its programs for 2026?

Denali Therapeutics is highlighting an update on its programs and expected milestones for 2026 and its participation in the 44th Annual J.P. Morgan Healthcare Conference.

Under which item of Form 8-K did Denali Therapeutics (DNLI) furnish the 2026 outlook press release?

Denali Therapeutics furnished the press release under Item 7.01, Regulation FD Disclosure, and listed it under Item 9.01 as an exhibit.